

Eligible patients aged 40 or above with hypertension (n=1,511,034)

New prescription of ACE-I (n=428,379)

New prescription of CCB (n=398,986)

Exclusion of patients:

- Who discontinued use of ACE-I within the first year of follow-up (n=191,565)
- Who switched to CCB during the first year of follow-up (n=88,288)

Exclusion of patients:

- With a previous prescription of ACE-I / CCB or concurrent initiation of ACE-I and CCB (n=563,060)
- With a follow-up period < 1 year (n=44,689)
- With a diagnosis of AMD prior to or within the first year of ACE-I / CCB initiation (n=6,601)

Exclusion of patients:

- Who discontinued use of CCB within the first year of follow-up (n=68,954)
- Who switched to ACE-I during the first year of follow-up (n=25,595)

ACE-I cohort (n=53,832)

CCB Cohort (n=43,106)

For the intention to treat analysis, follow-up ends at the earliest of:

1. Patient death
2. Patient transfer out of practice
3. End of practice data collection
4. Study end date
5. Development of AMD

For the on treatment analysis, follow-up ends at the earliest of

1. Above scenarios
2. One year after discontinuation of exposure drug of interest
3. Switch to comparator drug